Chemoprevention of colorectal cancer by inhibition of cyclooxygenase-2 derived prostaglandin E2 signaling: Recent advances in basic biology

Yong I. Cha, Raymond N. DuBois

    Research output: Contribution to journalArticlepeer-review


    Experimental evidence collected over the past decade has revealed that targeting cyclooxygenase-2 (COX-2) may have some efficacy for chemoprevention of cancer. However, recent safety concerns over the long-term use of COX-2 selective inhibitors are prompting research aimed at identifying other specific targets downstream of COX-2. In this regard, several groups have found that NSAIDs and COX-2 selective inhibitors primarily reduce the production of prostaglandin (PG) E2, a biologically active lipid product of the COX-2 enzyme, which results in attenuation of PGE2 signaling in the tumor microenvironment. Therefore, a detailed understanding of the PGE 2 signaling pathway in transformed cells is critical to help identify novel and safer targets for effective prevention and/or treatment of cancer. Here we review the recent advances in elucidating the molecular mechanisms by which PGE2 promotes carcinogenesis.

    Original languageEnglish (US)
    Pages (from-to)60-65
    Number of pages6
    JournalCurrent Colorectal Cancer Reports
    Issue number2
    StatePublished - Mar 2006

    ASJC Scopus subject areas

    • Hepatology
    • Oncology
    • Gastroenterology


    Dive into the research topics of 'Chemoprevention of colorectal cancer by inhibition of cyclooxygenase-2 derived prostaglandin E<sub>2</sub> signaling: Recent advances in basic biology'. Together they form a unique fingerprint.

    Cite this